Skip to main content
. 2021 Jun 24;13:5001–5011. doi: 10.2147/CMAR.S314219

Table 5.

Summary of Recent Studies Using NLR as a Preoperative Diagnostic Marker

Author (Year) Type of Malignancy Number of Subjects Measurement NLR Cut-off value Comment
Non-Gynecologic
Zheng et al
(2018)
Glioma 750 NLR, LMR 2.25 Glioma vs acoustic neuroma, menigioma
Çolak et al
(2019)
Hodgkin lymphoma 26 NLR 5.8 Hodgkin lymphoma vs reactive lymphadenopathy
Adhyatma et al
(2019)
Prostate cancer 172 NLR, PLR, PSA 3.08 Prostate cancer vs BPH
Yapar et al
(2020)
Enchondroma and low-grade chondrosarcoma. 101 NLR, MLR 2.0 Cartilaginous tumors vs healthy control
Tezol et al
(2020)
Lymphoma in children 190 NLR, MLR, PLR, and RDW 3.17 Lymphoma vs reactive lymphadenopathy
Gynecologic
Eo et al
(2018)
EOC 229 NLR, LMR, PLR 2.64 Malignancy vs benign ovarian mass
Kim et al
(2010)
Uterine sarcoma 34 NLR, CA-125 2.12 Uterine sarcoma vs leiomyoma
Cho et al
(2016)
Uterine sarcoma 31 NLR 2.1 Uterine sarcoma vs leiomyoma
Zhang et al
(2020)
LMS 45 NLR, LDH, PLT 2.8 Uterine leiomyosarcoma vs leiomyoma
Present study LMS 79 NLR, CRP, LDH or combination 2.157 Uterine leiomyosarcoma vs leiomyoma

Abbreviations: EOC, epithelial ovarian cancer; NLR, neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RDW, red cell distribution width; PSA, prostate-specific antigen; CRP, C-reactive protein; LDH, lactate dehydrogenase; LMS, leiomyosarcoma; PLT, platelet.